Dr. Joseph Mikhael
Dr. Mikhael's primary research interest is in multiple myeloma and its related conditions (Waldenstrom's macroglobulinemia and amyloidosis). He also pursues research in medical education, benign hematology and pharmacoeconomics: Multiple myeloma, Waldenstrom's and amyloidosis. Principal investigator of multiple clinical trials in both newly diagnosed and relapsed disease. Many of these trials include novel agents as well as combination therapies. He also has an interest in the growing field of quality-of-life in multiple myeloma.
As of January 2018, Dr. Joseph Mikhael has joined the IMF (International Myeloma Foundation) as Chief Medical Officer. He will be working closely with the IMF’s Chair of the Board, Dr. Brian Durie, to advance the mission of the organization in research, education, advocacy and patient care to improve lives of patients with multiple myeloma.
Having been a professor of medicine at Mayo Clinic and a world-renowned expert in myeloma, Dr. Mikhael brings a wealth of this experience to this new role. He has conducted dozens of clinical trials in the field of myeloma and has contributed to the development of many novel drugs. He also served as the Associate Dean of Graduate Medical Education and the Deputy Director of the Mayo Clinic Comprehensive Cancer Center.
Dr. Mikhael also serves as a councilor on the American Society of Hematology (ASH) Executive and is involved in mentoring the next generation of hematologists. He did his medical training in Canada, having completed medical school at the University of Ottawa, his hematology training at the University of Toronto and a Multiple Myeloma Fellowship at Princess Margaret Hospital. He also has a Master’s degree in Education from the University of Toronto.
In addition, Dr. Mikhael will remain in clinical and academic medicine with City of Hope Cancer Center.
Michael Tuohy is a multiple myeloma patient and joins Dr. Mikhael in an interview with Dr. Pat Baccili.